Prevention of cardiovascular events (eg, death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin - PEGASUS

Study identifier:D5132C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2009-017242-30

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Medical condition

myocardial infarction

Phase

Phase 3

Healthy volunteers

No

Study drug

Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo

Sex

All

Actual Enrollment

21379

Study type

Interventional

Age

50 Years - 130 Years

Date

Study Start Date: 01 Oct 2010
Primary Completion Date: 01 Dec 2014
Study Completion Date: 01 Dec 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Dec 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria